Discovery of a Phosphoinositide 3-Kinase (PI3K) β/δ Inhibitor for the Treatment of Phosphatase and Tensin Homolog (PTEN) Deficient Tumors: Building PI3Kβ Potency in a PI3Kδ-Selective Template by Targeting Nonconserved Asp856

被引：29

作者：

Perreault, Stephane ^{[1
]}

Chandrasekhar, Jayaraman ^{[1
]}

Cui, Zhi-Hua ^{[1
]}

Evarts, Jerry ^{[1
,3
]}

Hao, Jia ^{[2
]}

Kaplan, Joshua A. ^{[2
]}

Kashishian, Adam ^{[1
]}

Keegan, Kathleen S. ^{[1
]}

Kenney, Thomas ^{[1
]}

Koditek, David ^{[2
]}

Lad, Latesh ^{[2
]}

Lepist, Eve-Irene ^{[2
]}

McGrath, Mary E. ^{[2
]}

Patel, Leena ^{[1
]}

Phillips, Bart ^{[2
]}

Therrien, Joseph ^{[1
]}

Treiberg, Jennifer ^{[1
]}

Yahiaoui, Anella ^{[1
]}

Phillips, Gary ^{[1
]}

机构：

[1] Gilead Sci Inc, 199 E Blaine St, Seattle, WA 98102 USA

[2] Gilead Sci Inc, 333 Lakeside Dr, Foster City, CA 94404 USA

[3] Acerta Pharma, 15400 SE 30th Pl,Suite 206, Bellevue, WA 98007 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2017年 / 60卷 / 04期

关键词：

SELECTIVE PI3K-BETA; BIOLOGICAL EVALUATION; RECEPTOR ANTAGONISTS; RATIONAL DESIGN; CANCER; PATHWAY; DERIVATIVES; IDELALISIB; SERIES; BIOISOSTERES;

D O I：

10.1021/acs.jmedchem.6b01821

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Phosphoinositide 3-kinase (PI3K) beta signaling is required to sustain cancer cell growth in which the tumor suppressor phosphatase and tensin homolog (PTEN) has been deactivated. This manuscript describes the discovery, optimization, and in vivo evaluation of a novel series of PI3K beta/delta inhibitors in which PI3K beta potency was built in a PI3K delta-selective template. This work led to the discovery of a highly selective PI3K beta/delta inhibitor displaying excellent pharmacokinetic profile and efficacy in a human PTEN-deficient LNCaP prostate carcinoma xenograft tumor model.

引用

页码：1555 / 1567

页数：13

共 50 条

[31] Modulating the PI3K Signalling Pathway in Activated PI3K Delta Syndrome: a Clinical Perspective
Berglund, Lucinda J.
JOURNAL OF CLINICAL IMMUNOLOGY, 2024, 44 (01)
[32] TOTAL SYNTHESES OF LIPHAGAL: A POTENT AND SELECTIVE PHOSPHOINOSITIDE 3-KINASE α (PI3Kα) INHIBITOR FROM THE MARINE SPONGE AKA CORALLIPHAGA
Narita, Koichi
Katoh, Tadashi
HETEROCYCLES, 2018, 96 (01) : 3 - 41
[33] Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases
Erra, Montse
Taltavull, Joan
Greco, Angelique
Javier Bernal, Francisco
Francisco Caturla, Juan
Gracia, Jordi
Dominguez, Maria
Sabate, Mar
Paris, Stephane
Soria, Salome
Hernandez, Begona
Armengol, Clara
Cabedo, Judit
Bravo, Monica
Calama, Elena
Miralpeix, Montserrat
Lehner, Martin D.
ACS MEDICINAL CHEMISTRY LETTERS, 2017, 8 (01): : 118 - 123
[34] Discovery of fluoroquinolone derivatives as potent, selective inhibitors of PI3Kγ
Sha, Shao
Han, Hong-Wei
Gao, Fei
Liu, Tian-Bao
Li, Zhen
Xu, Chi
Zhong, Wei-Qing
Zhu, Hai-Liang
MEDCHEMCOMM, 2015, 6 (11) : 2029 - 2035
[35] Targeting PI3K signaling in cancer: Challenges and advances
De Santis, Maria Chiara
Gulluni, Federico
Campa, Carlo Cosimo
Martini, Miriam
Hirsch, Emilio
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2019, 1871 (02): : 361 - 366
[36] Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas
Xie, Shaozhen
Ni, Jing
McFaline-Figueroa, J. Ricardo
Wang, Yanzhi
Bronson, Roderick T.
Ligon, Keith L.
Wen, Patrick Y.
Roberts, Thomas M.
Zhao, Jean J.
CELL REPORTS, 2020, 32 (13):
[37] Insulin-Driven PI3K-AKT Signaling in the Hepatocyte Is Mediated by Redundant PI3Kα and PI3Kβ Activities and Is Promoted by RAS
Molinaro, Angela
Becattini, Barbara
Mazzoli, Arianna
Bleve, Augusto
Radici, Lucia
Maxvall, Ingela
Sopasakis, Victoria Rotter
Molinaro, Antonio
Backhed, Fredrik
Solinas, Giovanni
CELL METABOLISM, 2019, 29 (06) : 1400 - +
[38] Discovery and antiplatelet activity of a selective PI3Kβ inhibitor (MIPS-9922)
Zheng, Zhaohua
Pinson, Jo-Anne
Mountford, Simon J.
Orive, Stephanie
Schoenwaelder, Simone M.
Shackleford, David
Powell, Andrew
Nelson, Erin M.
Hamilton, Justin R.
Jackson, Shaun P.
Jennings, Ian G.
Thompson, Philip E.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 122 : 339 - 351
[39] Discovery and Optimization of a Series of Benzothiazole Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors
D'Angelo, Noel D.
Kim, Tae-Seong
Andrews, Kristin
Booker, Shon K.
Caenepeel, Sean
Chen, Kui
D'Amico, Derin
Freeman, Dan
Jiang, Jian
Liu, Longbin
McCarter, John D.
Miguel, Tisha San
Mullady, Erin L.
Schrag, Michael
Subramanian, Raju
Tang, Jin
Wahl, Robert C.
Wang, Ling
Whittington, Douglas A.
Wu, Tian
Xi, Ning
Xu, Yang
Yakowec, Peter
Yang, Kevin
Zalameda, Leeanne P.
Zhang, Nancy
Hughes, Paul
Norman, Mark H.
JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (06) : 1789 - 1811
[40] Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections
McPhail, Jacob A.
Burke, John E.
DRUGGABLE LIPID SIGNALING PATHWAYS, 2020, 1274 : 203 - 222

← 1 2 3 4 5 →